MA35941B1 - Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale - Google Patents

Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale

Info

Publication number
MA35941B1
MA35941B1 MA37360A MA37360A MA35941B1 MA 35941 B1 MA35941 B1 MA 35941B1 MA 37360 A MA37360 A MA 37360A MA 37360 A MA37360 A MA 37360A MA 35941 B1 MA35941 B1 MA 35941B1
Authority
MA
Morocco
Prior art keywords
dihydrochinazoline
derivative
pharmaceutical preparation
preparation containing
antiviral action
Prior art date
Application number
MA37360A
Other languages
English (en)
Inventor
Kerstin Paulus
Wilfried Schwab
Dominique Grunder
Hoogevest Peter Van
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35941(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of MA35941B1 publication Critical patent/MA35941B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des préparations pharmaceutiques, notamment conçues pour une administration par voie intraveineuse, qui contiennent de l'acide {8-fluoro-2-[4-(3-méthoxyphényl)pipérazin-1-yl]-3-[2-méthoxy-5-(trifluorométhyl)phényl]
MA37360A 2012-02-29 2014-09-17 Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale MA35941B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012101680A DE102012101680A1 (de) 2012-02-29 2012-02-29 Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
PCT/EP2013/054114 WO2013127970A1 (fr) 2012-02-29 2013-02-28 Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale

Publications (1)

Publication Number Publication Date
MA35941B1 true MA35941B1 (fr) 2014-12-01

Family

ID=47757622

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37360A MA35941B1 (fr) 2012-02-29 2014-09-17 Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale

Country Status (37)

Country Link
US (1) US10603384B2 (fr)
EP (3) EP4328218A3 (fr)
JP (1) JP6387486B2 (fr)
KR (1) KR102149561B1 (fr)
CN (2) CN110433166A (fr)
AU (1) AU2013224947B2 (fr)
BR (1) BR112014020946B1 (fr)
CA (1) CA2865203C (fr)
CL (1) CL2014002306A1 (fr)
CO (1) CO7061076A2 (fr)
CY (1) CY1121910T1 (fr)
DE (1) DE102012101680A1 (fr)
DK (2) DK3556350T3 (fr)
EA (1) EA026584B1 (fr)
ES (2) ES2741698T3 (fr)
FI (1) FI3556350T3 (fr)
HR (2) HRP20240197T1 (fr)
HU (2) HUE045949T2 (fr)
IL (1) IL234363B (fr)
IN (1) IN2014MN01892A (fr)
LT (2) LT3556350T (fr)
MA (1) MA35941B1 (fr)
ME (1) ME03448B (fr)
MX (1) MX369666B (fr)
MY (1) MY172310A (fr)
NZ (1) NZ628444A (fr)
PH (1) PH12014501937B1 (fr)
PL (2) PL2819648T3 (fr)
PT (2) PT3556350T (fr)
RS (2) RS65137B1 (fr)
SG (1) SG11201405294XA (fr)
SI (2) SI3556350T1 (fr)
SM (2) SMT201900458T1 (fr)
TN (1) TN2014000345A1 (fr)
UA (1) UA111415C2 (fr)
WO (1) WO2013127970A1 (fr)
ZA (1) ZA201405949B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
US10442773B2 (en) * 2013-06-19 2019-10-15 Aicuris Anti-Infective Cures Gmbh Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
AU2017274722A1 (en) 2016-06-03 2019-01-17 Atreya Innovations Private Limited A device for the detection and reliable capturing of the pulse characteristics
ES3015371T3 (en) * 2017-03-06 2025-05-05 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2020112542A1 (fr) 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations
PY2116992A (es) * 2020-02-27 2022-04-05 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
AR121438A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN113880776B (zh) * 2021-11-16 2023-06-16 山东诚创蓝海医药科技有限公司 一种莱特莫韦中间体的制备方法
UY40078A (es) 2021-12-21 2023-06-30 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin
CN118574603A (zh) * 2022-02-23 2024-08-30 株式会社Lg化学 包含异𫫇唑啉衍生物的注射制剂及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
WO2024037485A1 (fr) * 2022-08-15 2024-02-22 上海迪赛诺化学制药有限公司 Procédé de préparation d'une forme amorphe de letermovir
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法
CN119015222B (zh) * 2024-08-28 2025-12-09 石家庄四药有限公司 一种来特莫韦注射液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (fr) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone et ses derives
CA1284994C (fr) * 1985-08-05 1991-06-18 Murray Arthur Kaplan Sels de cephalosporine, et compositions injectables
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
NZ514195A (en) * 1999-03-17 2004-05-28 Astrazeneca Ab Amide derivatives
WO2001091751A1 (fr) * 2000-05-30 2001-12-06 Novo Nordisk A/S Nouvelle composition pharmaceutique et son procede de preparation
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
PL1689724T3 (pl) * 2003-11-25 2012-05-31 Novartis Ag Związki chinazolinonowe jako leki przeciwnowotworowe
WO2006086464A2 (fr) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones utilisees comme modulateurs de la 5ht
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
US8743287B2 (en) * 2009-07-24 2014-06-03 Broadcom Corporation Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction

Also Published As

Publication number Publication date
US10603384B2 (en) 2020-03-31
HRP20240197T1 (hr) 2024-04-26
EP4328218A2 (fr) 2024-02-28
DE102012101680A1 (de) 2013-08-29
EA201400963A1 (ru) 2015-02-27
JP6387486B2 (ja) 2018-09-12
ES2972133T3 (es) 2024-06-11
PH12014501937B1 (en) 2022-07-15
FI3556350T3 (fi) 2024-02-14
EP3556350A1 (fr) 2019-10-23
EP4328218A3 (fr) 2024-04-10
SMT201900458T1 (it) 2019-11-13
AU2013224947A1 (en) 2014-09-18
HUE045949T2 (hu) 2020-01-28
DK2819648T3 (da) 2019-08-26
KR20140130683A (ko) 2014-11-11
EP2819648A1 (fr) 2015-01-07
CL2014002306A1 (es) 2014-11-28
US20150133461A1 (en) 2015-05-14
NZ628444A (en) 2016-07-29
WO2013127970A1 (fr) 2013-09-06
ZA201405949B (en) 2021-07-28
HUE065553T2 (hu) 2024-06-28
LT2819648T (lt) 2019-09-10
LT3556350T (lt) 2024-02-26
KR102149561B1 (ko) 2020-08-31
AU2013224947B2 (en) 2017-06-29
PL3556350T3 (pl) 2024-05-06
CA2865203C (fr) 2019-11-05
MX369666B (es) 2019-11-14
MY172310A (en) 2019-11-21
PT2819648T (pt) 2019-09-05
BR112014020946B1 (pt) 2022-04-05
UA111415C2 (uk) 2016-04-25
IL234363B (en) 2020-04-30
SG11201405294XA (en) 2014-11-27
CY1121910T1 (el) 2020-10-14
EP2819648B1 (fr) 2019-05-29
HRP20191369T1 (hr) 2019-11-01
SI3556350T1 (sl) 2024-03-29
ME03448B (fr) 2020-01-20
MX2014010364A (es) 2014-12-05
DK3556350T3 (da) 2024-02-12
PT3556350T (pt) 2024-02-15
CN110433166A (zh) 2019-11-12
PL2819648T3 (pl) 2019-10-31
CN104144678A (zh) 2014-11-12
IN2014MN01892A (fr) 2015-07-10
CA2865203A1 (fr) 2013-09-06
RS59157B1 (sr) 2019-10-31
TN2014000345A1 (en) 2015-12-21
SMT202400068T1 (it) 2024-03-13
JP2015508801A (ja) 2015-03-23
RS65137B1 (sr) 2024-02-29
ES2741698T3 (es) 2020-02-12
PH12014501937A1 (en) 2014-11-24
EA026584B1 (ru) 2017-04-28
CO7061076A2 (es) 2014-09-19
BR112014020946A2 (fr) 2017-06-20
HK1205462A1 (en) 2015-12-18
SI2819648T1 (sl) 2019-10-30
EP3556350B1 (fr) 2024-01-10

Similar Documents

Publication Publication Date Title
MA35941B1 (fr) Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale
EP2868667A4 (fr) Agent thérapeutique à base d'anticorps anti-bmp9 en tant que principe actif, pour le traitement de l'anémie, notamment une anémie rénale et une anémie liée à un cancer
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MY166045A (en) Abeta antibody formulation
JO3459B1 (ar) تركيبات صيدلانية لعلاج مرض الزهايمر
MA38323B1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
TN2014000301A1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
EA201391018A1 (ru) Препараты иммуносупрессантов
MA39146A1 (fr) Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
EA201890532A1 (ru) Новые аннелированные бензамиды
EP3417853A4 (fr) Composition pharmaceutique pour le traitement d'un cancer, contenant un composé polyphénol utilisé comme principe actif
MA39983A (fr) Dérivés de carboxamide
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
EP2871187A4 (fr) Nouveau composé ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique le contenant à titre de principe actif
SI3079688T1 (en) A chromone derivative as a dopamine d3 receptor antagonist for its use in the treatment of autism spectrum disorder
MA35010B1 (fr) Inhibiteurs de la peptide déformylase
BR112012016549A2 (pt) piperazinas como agentes antimalariais
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant